Research ExplorerPublicationsDevelopment and validation of a disease-specific quality of ...

Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD)

Standard

Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD). / Arman, Ebru-Berrin; Augustin, Matthias; Mohr, Nicole; Debus, Sebastian E; Breuer, Peter; Blome, Christine.

In: J PATIENT-REP OUTCOM, Vol. 6, No. 1, 54, 27.05.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Arman, E-B, Augustin, M, Mohr, N, Debus, SE, Breuer, P & Blome, C 2022, 'Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD)', J PATIENT-REP OUTCOM, vol. 6, no. 1, 54. https://doi.org/10.1186/s41687-022-00451-0

APA

Arman, E-B., Augustin, M., Mohr, N., Debus, S. E., Breuer, P., & Blome, C. (2022). Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD). J PATIENT-REP OUTCOM, 6(1), [54]. https://doi.org/10.1186/s41687-022-00451-0

Vancouver

Arman E-B, Augustin M, Mohr N, Debus SE, Breuer P, Blome C. Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD). J PATIENT-REP OUTCOM. 2022 May 27;6(1). 54. https://doi.org/10.1186/s41687-022-00451-0

Bibtex

@article{9b547b5023df4a8d9dd00c6ad2298a0a,
title = "Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD)",
abstract = "BACKGROUND: The aim of this study was to develop and validate a short and feasible questionnaire to measure health-related quality of life (HRQoL) in patients with peripheral artery disease (PAD). The content of the new instrument is intended to correspond with the simultaneously developed instrument Patient Benefit Index for PAD (PBI-PAD), which evaluates treatment goals and benefits in this patient group.METHODS: Fifty patients stated their disease burden on free-text questionnaires, which was used by an interdisciplinary expert panel to develop 12 items for the new instrument, named Quality of Life questionnaire for patients with peripheral artery disease (QOLPAD). The validity of the instrument was tested in patients from Germany with PAD stages I to IV who completed the QOLPAD, EuroQol questionnaire (EQ-5D-3L; EuroQol visual analogue scale (EQ VAS)), and Vascular Quality of Life questionnaire (VascuQoL) before (baseline) and three months after (follow-up) treatment.RESULTS: One hundred and three patients were included at baseline (mean age: 68.6 years; 68% male), among whom, 57 provided data at follow-up. Most patients (86.4%) rated the completion of QOLPAD as being easy. Internal consistency was satisfactory, with a Cronbach's alpha of 0.74 (baseline) and 0.84 (follow-up). Convergent validity was indicated by significant correlations with the EQ-5D-3L (baseline: - 0.62; follow-up: - 0.81), EQ VAS (baseline: - 0.44, follow-up: - 0.79), VascuQoL global score (baseline: - 0.77; follow-up: - 0.87), global rating of impairment (baseline: 0.64; follow-up: 0.71), and PAD stage (baseline: 0.40; follow-up: 0.67). Sensitivity to change was confirmed by significant correlations of change in the QOLPAD with changes in convergent criteria; however, the high number of dropouts limits the generalizability of this finding.CONCLUSION: This study provided evidence that the QOLPAD is internally consistent and valid in patients receiving treatment for PAD in Germany.",
author = "Ebru-Berrin Arman and Matthias Augustin and Nicole Mohr and Debus, {Sebastian E} and Peter Breuer and Christine Blome",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = may,
day = "27",
doi = "10.1186/s41687-022-00451-0",
language = "English",
volume = "6",
journal = "J PATIENT-REP OUTCOM",
issn = "2509-8020",
publisher = "Springer International Publishing",
number = "1",

}

RIS

TY - JOUR

T1 - Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD)

AU - Arman, Ebru-Berrin

AU - Augustin, Matthias

AU - Mohr, Nicole

AU - Debus, Sebastian E

AU - Breuer, Peter

AU - Blome, Christine

N1 - © 2022. The Author(s).

PY - 2022/5/27

Y1 - 2022/5/27

N2 - BACKGROUND: The aim of this study was to develop and validate a short and feasible questionnaire to measure health-related quality of life (HRQoL) in patients with peripheral artery disease (PAD). The content of the new instrument is intended to correspond with the simultaneously developed instrument Patient Benefit Index for PAD (PBI-PAD), which evaluates treatment goals and benefits in this patient group.METHODS: Fifty patients stated their disease burden on free-text questionnaires, which was used by an interdisciplinary expert panel to develop 12 items for the new instrument, named Quality of Life questionnaire for patients with peripheral artery disease (QOLPAD). The validity of the instrument was tested in patients from Germany with PAD stages I to IV who completed the QOLPAD, EuroQol questionnaire (EQ-5D-3L; EuroQol visual analogue scale (EQ VAS)), and Vascular Quality of Life questionnaire (VascuQoL) before (baseline) and three months after (follow-up) treatment.RESULTS: One hundred and three patients were included at baseline (mean age: 68.6 years; 68% male), among whom, 57 provided data at follow-up. Most patients (86.4%) rated the completion of QOLPAD as being easy. Internal consistency was satisfactory, with a Cronbach's alpha of 0.74 (baseline) and 0.84 (follow-up). Convergent validity was indicated by significant correlations with the EQ-5D-3L (baseline: - 0.62; follow-up: - 0.81), EQ VAS (baseline: - 0.44, follow-up: - 0.79), VascuQoL global score (baseline: - 0.77; follow-up: - 0.87), global rating of impairment (baseline: 0.64; follow-up: 0.71), and PAD stage (baseline: 0.40; follow-up: 0.67). Sensitivity to change was confirmed by significant correlations of change in the QOLPAD with changes in convergent criteria; however, the high number of dropouts limits the generalizability of this finding.CONCLUSION: This study provided evidence that the QOLPAD is internally consistent and valid in patients receiving treatment for PAD in Germany.

AB - BACKGROUND: The aim of this study was to develop and validate a short and feasible questionnaire to measure health-related quality of life (HRQoL) in patients with peripheral artery disease (PAD). The content of the new instrument is intended to correspond with the simultaneously developed instrument Patient Benefit Index for PAD (PBI-PAD), which evaluates treatment goals and benefits in this patient group.METHODS: Fifty patients stated their disease burden on free-text questionnaires, which was used by an interdisciplinary expert panel to develop 12 items for the new instrument, named Quality of Life questionnaire for patients with peripheral artery disease (QOLPAD). The validity of the instrument was tested in patients from Germany with PAD stages I to IV who completed the QOLPAD, EuroQol questionnaire (EQ-5D-3L; EuroQol visual analogue scale (EQ VAS)), and Vascular Quality of Life questionnaire (VascuQoL) before (baseline) and three months after (follow-up) treatment.RESULTS: One hundred and three patients were included at baseline (mean age: 68.6 years; 68% male), among whom, 57 provided data at follow-up. Most patients (86.4%) rated the completion of QOLPAD as being easy. Internal consistency was satisfactory, with a Cronbach's alpha of 0.74 (baseline) and 0.84 (follow-up). Convergent validity was indicated by significant correlations with the EQ-5D-3L (baseline: - 0.62; follow-up: - 0.81), EQ VAS (baseline: - 0.44, follow-up: - 0.79), VascuQoL global score (baseline: - 0.77; follow-up: - 0.87), global rating of impairment (baseline: 0.64; follow-up: 0.71), and PAD stage (baseline: 0.40; follow-up: 0.67). Sensitivity to change was confirmed by significant correlations of change in the QOLPAD with changes in convergent criteria; however, the high number of dropouts limits the generalizability of this finding.CONCLUSION: This study provided evidence that the QOLPAD is internally consistent and valid in patients receiving treatment for PAD in Germany.

U2 - 10.1186/s41687-022-00451-0

DO - 10.1186/s41687-022-00451-0

M3 - SCORING: Journal article

C2 - 35622190

VL - 6

JO - J PATIENT-REP OUTCOM

JF - J PATIENT-REP OUTCOM

SN - 2509-8020

IS - 1

M1 - 54

ER -